Sold as Sodium Iodide I 123. Every FDA application for this active ingredient: 2 branded and 2 generic.
As of Nov 16, 2026, FDA lists 4 applications for Sodium Iodide I-123 (sold as Sodium Iodide I 123), first approved Mar 24, 1976, with 0 new uses approved and 0 published complete response letters.
| Mar 24, 1976 | Sodium Iodide I 123NDA 17630 · New molecular entity | Ge Healthcare | 11 | Discontinued |
| May 27, 1982 | Sodium Iodide I 123NDA 18671 · New formulation or manufacturer | Cardinal Health 418 | 11 | Marketed |
| Feb 28, 1989 | Sodium Iodide I 123ANDA 71909 | Curium | 3 | Marketed |
| Feb 28, 1989 | Sodium Iodide I 123ANDA 71910 | Curium | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA